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Abstract
Goals of work In preterminal cancer patients, provision of
palliative care in the patients’ own environment is pre-
ferred. The aim of the present study was to evaluate
patients’ and caregivers’ treatment adherence and patients’
acceptance of home infusions with adenosine 5′-triphos-
phate (ATP).
Patients and methods Preterminal cancer patients (life
expectancy <6 months) with mixed tumor types were
eligible for the study. Patients received a maximum of
eight weekly intravenous 8–10 h ATP infusions. Evaluation
of treatment adherence was based on registration of
protocol deviations and patients’ acceptance by structured
interviews with patients.
Main results Fifty-one patients received a total of 266
intravenous ATP infusions. The infusion protocol was well
executed: mean duration ≈8.30 h, stepwise achievement of
the maximum infusion rate within 30 min in 65% of the
infusions, and almost no delay in weekly administration.
All except one patient were not burdened by the adminis-
tration of the infusions at home and none of them had felt
afraid. The majority of patients found the advantages of the
ATP infusions outweighing the disadvantages. However, an
important bottleneck in the administration of ATP infusions
at home was difficulty in establishing venous access.
Conclusion ATP infusions at home are well accepted by
patients. Difficulties in establishing venous access might be
reduced by composing specialized home infusion teams
working both at the day care center and at home or by
adopting an alternative route of venous access.
Keywords ATP. Treatment adherence . Home infusion .
Palliative care
Introduction
Over the past 15 to 20 years, a major change in the delivery
of health care has occurred. Increasing numbers of patients
suffering from different diseases receive intravenous
therapy at home including intravenous antibiotics, steroids,
biphosphonates, and parenteral nutrition [8–11, 14, 17, 19, 20].
Also in cancer care, home administration of intravenous
medication (chemotherapy, opiates) is becoming a widely
used alternative to treatment in hospital [7, 14, 17]. Especially
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in terminally ill cancer patients, it is preferred to provide
palliative care in their own environment [18, 19].
A potential agent in palliative care is adenosine 5′-
triphosphate (ATP). A randomized clinical trial in patients
with advanced non-small cell lung cancer [3, 4] showed
that ATP infusions had marked favorable effects on body
weight, muscle strength, fatigue, nutritional intake, quality
of life, and survival [1, 3, 4].
Unfortunately, ATP cannot be given by alternative routes
of administration like oral application or hypodermoclysis.
In studies published so far, ATP infusions were given in a
clinical setting. However, several authors [2, 12, 13] have
reported that continuous application of low-dose ATP is
generally safe. Dyspnea, chest discomfort, and the urge to
take a deep breath were the most common side effects; all
side effects were mild and transient, resolving within
minutes after lowering the ATP dose. No symptoms of
cardiac ischemia occurred in any of the infusions [2, 5].
Because of the favorable safety profile of ATP and to
diminish the burden on the patients, we decided to
administer ATP at the patient’s home. The aim of the
present study was to evaluate patients’ and caregivers’
treatment adherence to the ATP infusion protocol and
patients’ acceptance of ATP infusions at home.
Patients and methods
Patients
Patients were recruited through the Departments of Medical
Oncology and Pulmonology of five hospitals in the
southern half of The Netherlands (located in Maastricht,
Eindhoven, Utrecht, and Heerlen) and through 50 general
practitioners in the region of Maastricht. Eligible for the
study were patients with cytologically or histologically
confirmed cancer, for whom medical treatment options
were restricted to supportive care, who had a life
expectancy <6 months, and had a World Health Organiza-
tion (WHO) performance status 1 or 2. Since the present
study was part of a randomized clinical trial aiming to study
the effects of ATP on nutritional status and fatigue, eligible
patients also had to suffer from at least one of the following
complaints: fatigue, anorexia, or weight loss >5% over the
previous 6 months. Excluded were patients with symptom-
atic angina pectoris, symptomatic heart failure, or any form
of atrioventricular block (assessed by electrocardiogram),
life expectancy <4 weeks, concurrent palliative chemother-
apy, and cognitive dysfunction. After baseline measure-
ments, patients were randomly allocated to ATP or control
treatment, using computer-generated random numbers with
permutation blocks of four. One hundred patients were
randomly assigned to the ATP (n=51) or control (n=49)
group. The present report on treatment adherence and
patients’ acceptance of ATP administration at home is
restricted to all 51 patients randomized to ATP treatment.
Baseline characteristics of ATP-treated patients are shown
in Table 1. The study was approved by the Ethical
Committees of all hospitals involved in the study, and all
patients signed written informed consent prior to the study.
Details of the trial design have been published elsewhere [6].
Treatment protocol
Over a period of 8 weeks, patients received eight ATP
courses of 8–10 h each, at weekly intervals. To prevent side
effects, all ATP infusions started beginning at a dose of
20 mcg/kg.min and were increased in steps of 10 mcg/kg.
min every 10 min until a maximum dose of 50 mcg/kg.min,
or in case of side effects, until the maximally tolerated dose
(MTD) had been reached. Thereafter, ATP was infused at a
constant rate. Since initiation of ATP infusions under
medical supervision in a clinical setting would facilitate
the treatment of possible side effects, the first two ATP
infusions were given at the day care center of the
participating hospitals. Based on the mild character of the
noted side effects during the first two infusions in the first
22 patients, in order to minimize hospitalization of these
preterminal patients, an amendment was granted by the
Ethical Committee during the study for administering only
the first ATP infusion at the day care center. All subsequent
infusions were administered at home by experienced,
highly qualified, and trained nurses of the infusion team
of the regional Home Care Organization or hospital.
Eligibility for home infusion therapy was checked using
specific criteria (Table 2). Patients and their informal
Table 1 Baseline characteristics of ATP-treated patients (n=51)
Number Percent










Gastrointestinal other 6 12
Prostate 5 10
Other 11 21
aWHO 1—restricted in physically strenuous activity but ambulatory
and able to do light work; WHO 2—ambulatory (not more than 50%
in bed) and capable of self-care but unable to carry out any work
bMean (range)
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caregivers were instructed in detail on the infusion
procedures and to call the infusion team in case of side
effects or any other problems. All participating nurses
received special instructions (verbal and written) on how to
administer, increase, and end the ATP infusions; what to do
in case of side effects; which items had to be checked and
reported; and how to instruct the patient and/or informal
caregiver.
Data collection and analysis
Patients’ adherence was evaluated by registering the
number of patients who stopped with the ATP infusions
before the end of the study and the reasons for drop out.
Patients’ acceptance was investigated by structured inter-
views after four and eight infusions. Only the latest
available evaluation was processed for the present paper.
These interviews included questions about burden, dura-
tion, frequency, and perceived benefits and disadvantages
of the infusions as well as feelings of anxiety during the
infusions. Adherence to the treatment protocol was evalu-
ated by standardized registration of the course of the
infusions and all protocol deviations. All data were
analyzed in a descriptive way using SPSS 13.0 for
Windows.
Results
Patients’ adherence to ATP administration
Of the 51 included patients, 6% did not start with ATP
infusions, 29% received one to three courses, 18% four
to seven courses, and 47% completed all eight infusions
(Fig. 1). Twelve patients decided to continue ATP
administration after completion of the eight regular
infusions.
Six patients died during the intervention period. Twenty-
one patients stopped or did not start with ATP infusions for
reasons of deterioration in medical condition (n=14), fear
of side effects (n=4), or being unsatisfied with the effect of
the ATP (n=3).
Acceptance by patients
Twenty-nine patients (57% of total) were interviewed
about their experiences with ATP infusions at home.
Twenty-two patients were not assessable because of death
or deterioration in medical condition. All except one
patient were not burdened by the home infusions.
Patients mentioned that it was more relaxed at home
and that it was possible to continue daily activities in
one’s own environment. The infusion frequency of once
a week was evaluated as “good” by 25 patients. The
duration of 8–10 h was experienced as too long by 11
patients, although many patients added that they accepted
the infusion duration that was perceived necessary for
obtaining maximal results. None of the patients had felt
afraid during the home infusions. Twenty-one patients
found the advantages of the ATP infusions outweighing
the disadvantages. Main disadvantages of home infusions
mentioned by patients were problems with establishing
venous access, restriction of daily activities by the
infusion, and burden for the informal caregiver.
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Fig. 1 Flow diagram of the study
Table 2 Eligibility criteria for home infusion therapy
Appropriate housing situation and sanitary conditions
Telephone or comparable device for external communication
Presence of informal caregiver in the home
Psychological ability of patient and family to cope with the potential
stress of home infusions
Motivation of patient and informal care giver for home infusions
Acceptance of responsibility for the home infusions, i.e., to report side
effects and/or to stop the infusion in case this would be needed
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Protocol adherence
A summary of protocol deviations is given in Table 3. Of the
408 planned ATP infusions, 142 infusions were not adminis-
tered due to deterioration of medical condition or death.
Of the 266 infusions given, 95 infusions (36%) were
administered at the day care center of the participating
hospitals and 171 infusions (64%) at home. In eight patients,
more than two infusions were given at the day care center.
Reasons for this were, among other things, fear of side effects
or the unavailability of an informal caregiver.
The mean duration of the ATP infusions at home was 8 h
33 min (standard deviation (SD) 1 h 35 min). The mean
period to reach the MTD amounted to 27 min at home.
According to the study protocol, nurses were to stay with
the patient for 30 min after reaching the MTD. The total
spent time was ≈1 h at the start of each infusion and ≈0.5 h
at the end of each infusion. In 22 out of 266 infusions, the
home nurse had been called during the infusion and had to
visit the patient to solve the problems (side effects, infusion
pump alarm, etc.), implicating an additional time invest-
ment varying from 30–90 min.
Discussion
The objective of this study was to evaluate treatment
adherence and patients’ acceptance of ATP infusions at
home in patients with preterminal cancer. As far as we
know, this is the first study in which ATP infusions have
been systematically administered at home. Results show
that the administration of the infusions was largely carried
out according to protocol: mean duration ≈8.30 h, stepwise
achievement of the maximum infusion rate within 30
minutes in 65% of the infusions, and almost no delay in
weekly administration.
However, an important bottleneck in the administration
of ATP infusions at home was difficulty in establishing
venous access, possibly due to the history of chemotherapy
in many patients. As far as we know, little is written about
this problem in the literature. In most studies, venous access
devices (Port-a-cath, peripherally inserted central catheter
(PICC), or peripheral venous cannula) were inserted during
hospital stay or at the day care unit and left in place when
the patient went home [8, 14, 17, 20]. In our study, the
peripheral venous cannula had to be inserted at home by the
home nurse of the infusion team. Lapostolle et al. [15]
reported a study on a total of 671 attempts to obtain
peripheral intravenous access in 495 patients in emergency
care in out-of-hospital settings. The first attempt was
successful in 368 cases (74%) and unsuccessful in 127
(26%). Peripheral intravenous access was finally achieved
in 99% of the patients. Improved success rate was reported
when attempts were performed by a nurse specialized in
emergency care in patients without a particular medical
history like chemotherapy, diabetes, or previous multiple
hospitalizations. Initial teaching and regular practice signi-
ficantly increased the success rate [15].
Table 3 Protocol and deviations from protocol
Protocol Actual performance of ATP administration
Number of infusions 408 infusions planned
(8 infusions×51 patients)
266 infusions administered
0 infusions 3 patients (6%)
1–3 infusions 15 patients (29%)
4–7 infusions 9 patients (18%)
8 infusions 24 patients (47%)
Mean duration
of infusions
8–10 h Day care center 8 h 05 min±0 h 49 min (mean±SD)
At home 8 h 33 min±1 h 35 min
Run in period 30–45 min <30 min 172 infusions (65%)
30–45 min 55 infusions (21%)
>45 min 27 infusions (10%)
Unknown 12 infusions (5%)
Frequency Once per week Once per week 263 infusions
Delayed for 14 days 3 infusions
Day care center:
95 infusions (36%)
First two infusions First infusion 25
First two infusions 15




Home infusion nurses Home infusion nurses 137 infusions (80%)
Day care center 25 infusions (15%)
Ambulance personnel 6 infusions (4%)
Hospital nurse at home 3 infusions (2%)
1422 Support Care Cancer (2008) 16:1419–1424
In our study, one of our participating centers solved the
problem of difficulties in establishing venous access by a
transmural infusion team composed of trained infusion
nurses working both at the hospital and in the home
situation, thus providing regular practice in inserting
infusion needles. Another solution would be to choose an
alternative route of venous access. In the present study, a
PICC was successfully inserted in one patient.
Our finding that most patients and informal caregivers
preferred home infusions is in accordance with other
studies. A study comparing hospital and home antibiotic
treatment for cellulitis showed that home care is the
preferred treatment choice by patients, particularly for those
patients who have experienced community care before [9].
In patients with colon cancer receiving chemotherapy,
global patient satisfaction with health care was greater in
patients receiving home chemotherapy than in patients
receiving outpatient treatment [7]. In a study in patients
with Fabry disease [16], most patients also preferred
treatment at home.
A considerable proportion of patients (38%) perceived
the duration of the infusions at home as too long. Further
investigations are warranted to explore other treatment
schedules. Technological development may allow smaller,
more mobile, and less noisy infusion pumps, contributing
to patient comfort.
No feelings of anxiety were reported by the patients in
the present study. Zimran et al. [20] also showed no
feelings of fear or anxiety associated with infusion
treatment at home. In contrast, study patients participating
in a self-administration program in which they had to
handle the venous access device themselves [14] did show
feelings of uncertainty and anxiety. With regard to the first
infusion, our study indicates that patients felt safe when this
infusion was administered at the day care center.
This evaluation study has some limitations. Inherent to
the study population of preterminal cancer patients is the
relatively small proportion of patients who completed all
eight infusions. This may have led to selection bias since
patients with the worst condition will drop out first,
restricting the evaluation to patients with fewer problems
and easier-to-administer infusions. Furthermore, for logistic
reasons, data for the present study had to be collected by
the same researcher who was involved in patient instruction
and organization of the infusion protocol. Even though
great care was taken to allow patients and caregivers to
freely express their opinion and feelings, the possibility of
biased information by socially desired answers cannot be
completely disregarded.
Despite these limitations, we conclude that patients’ and
caregivers’ adherence to the ATP infusion protocol is high
and that ATP infusions at home are well accepted by
patients. Possibilities to increase the comfort for the patient
would be to perform the infusion during the night.
Difficulties in establishing venous access might be reduced
by composing specialized home infusion teams working
both at the day care center and at home or by adopting an
alternative route of venous access.
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